CAR.AU

39.48

+0.61%↑

WOR.AU

14.64

+0.55%↑

AZJ.AU

3.19

+0.31%↑

RSG.AU

0.69

0%↓

CAR.AU

39.48

+0.61%↑

WOR.AU

14.64

+0.55%↑

AZJ.AU

3.19

+0.31%↑

RSG.AU

0.69

0%↓

CAR.AU

39.48

+0.61%↑

WOR.AU

14.64

+0.55%↑

AZJ.AU

3.19

+0.31%↑

RSG.AU

0.69

0%↓

CAR.AU

39.48

+0.61%↑

WOR.AU

14.64

+0.55%↑

AZJ.AU

3.19

+0.31%↑

RSG.AU

0.69

0%↓

CAR.AU

39.48

+0.61%↑

WOR.AU

14.64

+0.55%↑

AZJ.AU

3.19

+0.31%↑

RSG.AU

0.69

0%↓

Kodu・Aktsiate loetelu・CSL Ltd

CSL Ltd

Suletud

SektorTööstus

210.17 0.15

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

209.19

Max

210.4

Põhinäitajad
By Trading Economics
Sissetulek	2B
Müük	-5.7B 2.5B
P/E Sektori keskmine	21.941 38.367
Aktsiakasum	2.04
Dividenditootlus	1.39
Kasumimarginaal	24.437
Töötajad	29,904
EBITDA	-2.4B 858M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+35.44% upside

Dividendid
By Dow Jones
Dividenditootlus Sektori keskmine	1.39% 2.26%

Turustatistika
By TradingEconomics
Turukapital	-24B 100B
Eelmine avamishind	210.02
Eelmine sulgemishind	210.17

Uudiste sentiment

By Acuity

38%

62%

142 / 459 Pingereas Industrials

CSL Ltd Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

19. aug 2025, 03:32 UTC

Suurimad hinnamuutused turgudel

CSL Shares Slide 13% After Earnings, Seqirus Spin-Off Announcement

18. aug 2025, 23:46 UTC

Tulu

CSL to Spin Off Seqirus, Cut Up to 15% of Staff in Sweeping Restructure -- Update

18. aug 2025, 22:15 UTC

Tulu

CSL to Cut Up to 15% of Staff in $770 Million Restructure

9. apr 2025, 09:39 UTC

Suurimad hinnamuutused turgudel

Pharma Stocks Tumble After Trump Threatens Tariffs on Medicines

10. veebr 2025, 21:55 UTC

Tulu

CSL Lifts 1st Half Net Profit by 3%, Led by Blood-Plasma Business -- Update

10. veebr 2025, 21:34 UTC

Tulu

CSL Lifts 1st Half Net Profit by 3%, Led by Blood-Plasma Business

18. aug 2025, 23:46 UTC

Market Talk

Tulu

Investors May Have Lukewarm Reception to CSL's Earnings, Restructure -- Market Talk

18. aug 2025, 21:52 UTC

Tulu

CSL to Record Up to $700M-$770M in FY26 Restructuring Costs>CSL.AU

18. aug 2025, 21:51 UTC

Tulu

CSL to Cut Up to 15% of Staff>CSL.AU

18. aug 2025, 21:49 UTC

Tulu

CSL Says It Closed 22 Underperforming U.S. Plasma Centers in August>CSL.AU

18. aug 2025, 21:49 UTC

Tulu

CSL: Combination Will Deliver Synergies, Revenue Growth Opportunities>CSL.AU

18. aug 2025, 21:48 UTC

Tulu

CSL to Combine Behring and Vifor Medical and Commercial Functions>CSL.AU

18. aug 2025, 21:47 UTC

Tulu

CSL to Integrate R&D, Business Development, Commercial Teams>CSL.AU

18. aug 2025, 21:46 UTC

Tulu

CSL: Transformational Initiatives to Reduce Costs, Simplfy Decision Making>CSL.AU

18. aug 2025, 21:45 UTC

Tulu

CSL to Launch Multiyear Share Buyback in Fiscal 2026>CSL.AU

18. aug 2025, 21:45 UTC

Tulu

CSL Intends Seqirus to Be Listed on the ASX>CSL.AU

18. aug 2025, 21:44 UTC

Tulu

CSL Intends to Demerge Seqirus by End of FY 2026>CSL.AU

18. aug 2025, 21:43 UTC

Tulu

CSL Raises Dividend to $1.62 Vs. $1.45 >CSL.AU

18. aug 2025, 21:43 UTC

Tulu

CSL FY Underlying Net Profit $3.22B Vs. $2.91B>CSL.AU

18. aug 2025, 21:42 UTC

Tulu

CSL FY Rev $15.56B Vs. $14.80B >CSL.AU

18. aug 2025, 21:42 UTC

Tulu

CSL FY Net $3.00B Vs. Net $2.64B >CSL.AU

17. juuni 2025, 02:15 UTC

Market Talk

Higher Margins Offered by CSL's Andembry Will Lift Earnings -- Market Talk

9. apr 2025, 07:01 UTC

Market Talk

CSL May Need to Raise Prices to Offset Trump's Potential Pharma Tariffs -- Market Talk

21. märts 2025, 02:03 UTC

Market Talk

Severe U.S. Influenza Season Could Benefit CSL -- Market Talk

11. veebr 2025, 22:30 UTC

Market Talk

Flu Vaccines Proving Problematic for CSL -- Market Talk

10. veebr 2025, 21:40 UTC

Tulu

CSL Lifts 1H Net Profit by 3%, Led by Blood-Plasma Business -- Update

10. veebr 2025, 21:19 UTC

Tulu

CSL Lifts 1H Net Profit by 3%, Led by Blood-Plasma Business

10. veebr 2025, 21:13 UTC

Tulu

CSL Reaffirms Guidance for FY 2025 Net Profit of US$3.2 Billion-US$3.3 Billion at Constant FX

10. veebr 2025, 21:12 UTC

Tulu

CSL Interim Dividend US$1.30/Security

10. veebr 2025, 21:12 UTC

Tulu

CSL 1H Revenue US$8.48 Billion, Up 5% on Year

Võrdlus sarnastega

Hinnamuutus

CSL Ltd Prognoos

Hinnasiht

By TipRanks

35.44% tõus

12 kuu keskmine prognoos

Keskmine 283.415 AUD 35.44%

Kõrge 330 AUD

Madal 227.5 AUD

Põhineb 13 Wall Streeti analüütiku instrumendi CSL Ltd 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

13 ratings

Osta

Hoia

Müü

Põhineb 13 analüütiku instrumendi CSL Ltd aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

142 / 459 Pingereas Tööstus

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest CSL Ltd

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.